Glucose regulation by newly synthesized boronic acid functionalized molecules as dipeptidyl peptidase IV inhibitor: a potential compound for therapeutic intervention in hyperglycaemia

• Published in: Journal of biomolecular structure & dynamics Vol. 42; no. 6; pp. 2859 - 2871
• Main Authors: Prajapati, Namrata, Sharma, Dilip, Ashok Bidve, Pankaj, Chouhan, Deepak, Allani, Meghana, kumar Patel, Sagar, Ghosh Chowdhury, Moumita, Shard, Amit, Tiwari, Vinod
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 12.04.2024
• Subjects: Animals; Blood Glucose - metabolism; Body Weight; boronic acid; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl-Peptidase IV Inhibitors - pharmacology; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; DPP4 enzyme; Gastric Inhibitory Polypeptide - metabolism; Gastric Inhibitory Polypeptide - therapeutic use; Glucose; Hyperglycemia - chemically induced; Hyperglycemia - drug therapy; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Rats; sitagliptin; glucose; DPP4 enzyme; sitagliptin; Diabetes; boronic acid
• ISSN: 0739-1102; 1538-0254
• DOI: 10.1080/07391102.2023.2215319

Management of type 2 diabetes mellitus (T2DM) using dipeptidyl peptidase IV (DPP IV) inhibitors is gaining precedence as this enzyme plays an indispensable role in cleaving and inactivating peptides, such as glucagon-like peptide-1 (GLP-1), incretin hormones, and glucose-dependent insulinotropic polypeptide (GIP). There are several DPP IV inhibitors used to treat T2DM, but limited by side effects such as disturbed GIT, flu-like symptoms, etc. Thus, there is an urgent need for the development of novel and better DPP IV inhibitors for the management of the same. In the present study, we investigated the effect of new boronic acid-based thiazole compounds as DPP IV inhibitors. We used substituted anilines that were progressively modified through a multi-step synthesis and then chemically characterised. These molecules have good binding affinity and molecular interactions at the active site of the DPP IV enzyme. Two boronic acid-based molecules, i.e. PC06R58 and PC06R108, were used for the assessment of their in-vitro enzymatic activities. Both molecules (PC06108 and PC06R58) exhibited potent uncompetitive DPP IV enzyme inhibition at two different concentrations of 90.9 and 15.6 nM, respectively, compared to sitagliptin having an IC 50 of 17.3 nM. Furthermore, the oral glucose tolerance test suggested significantly reduced blood glucose levels at 20 mg/kg of the body weight upon administration of PC06R58 and PC06R108 molecules in rats after glucose ingestion (2 g/kg of the body weight). The compounds showed satisfactory DPP IV inhibition. Furthermore, DPP IV inhibitory activity and acceptable pre-ADME/Tox profile indicate it is a lead compound in this novel class of DPP IV inhibitors. Communicated by Ramaswamy H. Sarma